                         SEQUENCE LISTING

<110>  1GLOBE HEALTH INSTITUTE LLC
       LI, Chiang J.
       UNNIRAMAN, Shyam
 
<120>  SOLUBLE UNIVERSAL ADCC-ENHANCING SYNTHETIC FUSION GENE AND 
       PEPTIDE TECHNOLOGY AND ITS USE THEREOF

<130>  GHI-003PCT1

<140>  PCT/US 15/064572
<141>  2015-12-08

<150>  US 62/089,097
<151>  2014-12-08

<150>  US 62/200,557
<151>  2015-08-03

<160>  4     

<170>  PatentIn version 3.5

<210>  1
<211>  281
<212>  PRT
<213>  Homo sapiens

<400>  1

Met Trp Phe Leu Thr Thr Leu Leu Leu Trp Val Pro Val Asp Gly Gln 
1               5                   10                  15      


Val Asp Thr Thr Lys Ala Val Ile Thr Leu Gln Pro Pro Trp Val Ser 
            20                  25                  30          


Val Phe Gln Glu Glu Thr Val Thr Leu His Cys Glu Val Leu His Leu 
        35                  40                  45              


Pro Gly Ser Ser Ser Thr Gln Trp Phe Leu Asn Gly Thr Ala Thr Gln 
    50                  55                  60                  


Thr Ser Thr Pro Ser Tyr Arg Ile Thr Ser Ala Ser Val Asn Asp Ser 
65                  70                  75                  80  


Gly Glu Tyr Arg Cys Gln Arg Gly Leu Ser Gly Arg Ser Asp Pro Ile 
                85                  90                  95      


Gln Leu Glu Ile His Arg Gly Trp Leu Leu Leu Gln Val Ser Ser Arg 
            100                 105                 110         


Val Phe Thr Glu Gly Glu Pro Leu Ala Leu Arg Cys His Ala Trp Lys 
        115                 120                 125             


Asp Lys Leu Val Tyr Asn Val Leu Tyr Tyr Arg Asn Gly Lys Ala Phe 
    130                 135                 140                 


Lys Phe Phe His Trp Asn Ser Asn Leu Thr Ile Leu Lys Thr Asn Ile 
145                 150                 155                 160 


Ser His Asn Gly Thr Tyr His Cys Ser Gly Met Gly Lys His Arg Tyr 
                165                 170                 175     


Thr Ser Ala Gly Ile Ser Val Thr Val Lys Glu Leu Phe Pro Ala Pro 
            180                 185                 190         


Val Leu Asn Ala Ser Val Thr Ser Pro Leu Leu Glu Gly Asn Leu Val 
        195                 200                 205             


Thr Leu Ser Cys Glu Thr Lys Leu Leu Leu Gln Arg Pro Gly Leu Gln 
    210                 215                 220                 


Leu Tyr Phe Ser Phe Tyr Met Gly Ser Lys Thr Leu Arg Gly Arg Asn 
225                 230                 235                 240 


Thr Ser Ser Glu Tyr Gln Ile Leu Thr Ala Arg Arg Glu Asp Ser Gly 
                245                 250                 255     


Leu Tyr Trp Cys Glu Ala Ala Thr Glu Asp Gly Asn Val Leu Lys Arg 
            260                 265                 270         


Ser Pro Glu Leu Glu Leu Gln Val Leu 
        275                 280     


<210>  2
<211>  250
<212>  PRT
<213>  Artificial

<220>
<223>  Linker sequences with a humanized OKT3 sequence

<400>  2

Ser Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Gly 
1               5                   10                  15      


Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Lys Ser Ser 
            20                  25                  30          


Gly Tyr Thr Phe Thr Arg Tyr Thr Met His Trp Val Arg Gln Ala Pro 
        35                  40                  45              


Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Asn Pro Ser Arg Gly Tyr 
    50                  55                  60                  


Thr Asn Tyr Asn Gln Lys Val Lys Asp Arg Phe Thr Ile Ser Arg Asp 
65                  70                  75                  80  


Asn Ser Lys Asn Thr Ala Phe Leu Gln Met Asp Ser Leu Arg Pro Glu 
                85                  90                  95      


Asp Thr Gly Val Tyr Phe Cys Ala Arg Tyr Tyr Asp Asp His Tyr Cys 
            100                 105                 110         


Leu Asp Tyr Trp Gly Gln Gly Thr Pro Val Thr Val Ser Ser Val Glu 
        115                 120                 125             


Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Val Asp 
    130                 135                 140                 


Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
145                 150                 155                 160 


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Met 
                165                 170                 175     


Asn Trp Tyr Gln Gln Thr Pro Gly Lys Ala Pro Lys Arg Trp Ile Tyr 
            180                 185                 190         


Asp Thr Ser Lys Val Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser 
        195                 200                 205             


Gly Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu 
    210                 215                 220                 


Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Leu Thr 
225                 230                 235                 240 


Phe Gly Gln Gly Thr Lys Leu Gln Ile Thr 
                245                 250 


<210>  3
<211>  531
<212>  PRT
<213>  Artificial

<220>
<223>  fusion protein sequence for an Adapter-Like ADCC Enhancer 
       embodiment

<400>  3

Met Trp Phe Leu Thr Thr Leu Leu Leu Trp Val Pro Val Asp Gly Gln 
1               5                   10                  15      


Val Asp Thr Thr Lys Ala Val Ile Thr Leu Gln Pro Pro Trp Val Ser 
            20                  25                  30          


Val Phe Gln Glu Glu Thr Val Thr Leu His Cys Glu Val Leu His Leu 
        35                  40                  45              


Pro Gly Ser Ser Ser Thr Gln Trp Phe Leu Asn Gly Thr Ala Thr Gln 
    50                  55                  60                  


Thr Ser Thr Pro Ser Tyr Arg Ile Thr Ser Ala Ser Val Asn Asp Ser 
65                  70                  75                  80  


Gly Glu Tyr Arg Cys Gln Arg Gly Leu Ser Gly Arg Ser Asp Pro Ile 
                85                  90                  95      


Gln Leu Glu Ile His Arg Gly Trp Leu Leu Leu Gln Val Ser Ser Arg 
            100                 105                 110         


Val Phe Thr Glu Gly Glu Pro Leu Ala Leu Arg Cys His Ala Trp Lys 
        115                 120                 125             


Asp Lys Leu Val Tyr Asn Val Leu Tyr Tyr Arg Asn Gly Lys Ala Phe 
    130                 135                 140                 


Lys Phe Phe His Trp Asn Ser Asn Leu Thr Ile Leu Lys Thr Asn Ile 
145                 150                 155                 160 


Ser His Asn Gly Thr Tyr His Cys Ser Gly Met Gly Lys His Arg Tyr 
                165                 170                 175     


Thr Ser Ala Gly Ile Ser Val Thr Val Lys Glu Leu Phe Pro Ala Pro 
            180                 185                 190         


Val Leu Asn Ala Ser Val Thr Ser Pro Leu Leu Glu Gly Asn Leu Val 
        195                 200                 205             


Thr Leu Ser Cys Glu Thr Lys Leu Leu Leu Gln Arg Pro Gly Leu Gln 
    210                 215                 220                 


Leu Tyr Phe Ser Phe Tyr Met Gly Ser Lys Thr Leu Arg Gly Arg Asn 
225                 230                 235                 240 


Thr Ser Ser Glu Tyr Gln Ile Leu Thr Ala Arg Arg Glu Asp Ser Gly 
                245                 250                 255     


Leu Tyr Trp Cys Glu Ala Ala Thr Glu Asp Gly Asn Val Leu Lys Arg 
            260                 265                 270         


Ser Pro Glu Leu Glu Leu Gln Val Leu Ser Ser Gly Gly Gly Gly Ser 
        275                 280                 285             


Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
    290                 295                 300                 


Ser Leu Arg Leu Ser Cys Lys Ser Ser Gly Tyr Thr Phe Thr Arg Tyr 
305                 310                 315                 320 


Thr Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 
                325                 330                 335     


Gly Tyr Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Gln Lys Val 
            340                 345                 350         


Lys Asp Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Ala Phe 
        355                 360                 365             


Leu Gln Met Asp Ser Leu Arg Pro Glu Asp Thr Gly Val Tyr Phe Cys 
    370                 375                 380                 


Ala Arg Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr Trp Gly Gln Gly 
385                 390                 395                 400 


Thr Pro Val Thr Val Ser Ser Val Glu Gly Gly Ser Gly Gly Ser Gly 
                405                 410                 415     


Gly Ser Gly Gly Ser Gly Gly Val Asp Asp Ile Gln Met Thr Gln Ser 
            420                 425                 430         


Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys 
        435                 440                 445             


Arg Ala Ser Ser Ser Val Ser Tyr Met Asn Trp Tyr Gln Gln Thr Pro 
    450                 455                 460                 


Gly Lys Ala Pro Lys Arg Trp Ile Tyr Asp Thr Ser Lys Val Ala Ser 
465                 470                 475                 480 


Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr 
                485                 490                 495     


Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys 
            500                 505                 510         


Gln Gln Trp Ser Ser Asn Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu 
        515                 520                 525             


Gln Ile Thr 
    530     


<210>  4
<211>  1596
<212>  DNA
<213>  Artificial

<220>
<223>  DNA sequence for a fusion protein embodiment

<400>  4
atgtggtttc tgactacact gctgctgtgg gtgcccgtgg atggacaggt ggatactaca       60

aaagccgtga ttacactgca gcccccttgg gtgtctgtct tccaggagga aaccgtgaca      120

ctgcactgcg aggtcctgca tctgccaggc agctcctcta cccagtggtt tctgaacgga      180

actgctaccc agacatctac tcccagttac cgcatcacaa gcgcatccgt gaatgacagc      240

ggcgagtatc gatgccagcg ggggctgtca ggtcgaagcg atccaatcca gctggaaatt      300

caccgggggt ggctgctgct gcaggtgagt tcaagggtct tcaccgaggg tgaacccctg      360

gcactgaggt gtcacgcctg gaaggacaaa ctggtgtaca acgtcctgta ctatagaaat      420

ggcaaggcct tcaagttctt tcattggaac agcaatctga ctatcctgaa gaccaacatt      480

tctcacaatg gaacctacca ttgcagcgga atggggaagc atcgctatac ttctgctggg      540

atcagtgtga ccgtcaaaga actgttccca gctcccgtgc tgaacgcatc cgtcacatct      600

cctctgctgg aggggaatct ggtgacactg tcctgtgaaa ctaagctgct gctgcagcgg      660

ccaggactgc agctgtactt ctccttttat atgggctcta aaaccctgag aggacgcaac      720

acaagctccg agtaccagat tctgactgcc cggagggaag acagcgggct gtattggtgc      780

gaggccgcta ccgaagatgg taatgtgctg aagaggtccc ccgagctgga actgcaggtg      840

ctgtctagtg gcggaggggg tagtcaggtg cagctggtcc agtccggagg aggagtggtc      900

cagcctggca ggtcactgag actgagctgt aagtcaagcg gatacacctt cacaagatat      960

actatgcact gggtgcgcca ggctcctggt aaaggactgg agtggatcgg gtacattaac     1020

cctagcagag gttacacaaa ctataatcag aaggtgaaag accgcttcac aatctcccga     1080

gataactcta aaaatactgc ctttctgcag atggactccc tgagacctga ggataccggc     1140

gtgtactttt gcgctcgcta ctatgacgat cattactgtc tggattattg gggacagggg     1200

accccagtga cagtctcctc tgtggaaggt ggcagtggag ggtcaggtgg cagcggaggg     1260

tccggtggag tggacgatat ccagatgacc cagtctccca gttcactgtc tgccagtgtg     1320

ggcgaccggg tcactattac ctgcagggct agctcctctg tgagctacat gaattggtat     1380

cagcagaccc ctggcaaggc accaaaacga tggatctacg ataccagtaa ggtggcctca     1440

ggagtcccaa gccggttctc aggtagcggc tccggaacag actatacctt caccatcagt     1500

tcactgcagc ctgaggatat tgccacttac tattgtcagc agtggagtag taatcctctg     1560

acattcggac agggaaccaa actgcagatc acataa                               1596


